Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20344525 | 0.91 | MAPT (0.50) | ALDH1A1HPGDKDM4EL3MBTL1MAPT | |
| SCHEMBL2308150 | 0.90 | ALDH1A1 (0.61) | SMPD1ALDH1A1HPGDPTPN11 | |
| SCHEMBL9867832 | 0.85 | HDAC6 (0.54) | SMPD1ALDH1A1HPGDKDM4EL3MBTL1 | |
| SCHEMBL967401 | 0.83 | SMPD1 (0.67) | SMPD1ALDH1A1HPGDMGLLPTPN11 | |
| SCHEMBL9304902 | 0.83 | SMPD1 (0.67) | SMPD1ALDH1A1HPGDMGLLPTPN11 | |
| SCHEMBL24950547 | 0.83 | SMPD1 (0.67) | SMPD1ALDH1A1HPGDMGLLPTPN11 | |
| SCHEMBL9565566 | 0.83 | SMPD1 (0.67) | SMPD1ALDH1A1HPGDMGLLPTPN11 | |
| SCHEMBL7335792 | 0.81 | SMPD1 (0.64) | SMPD1ALDH1A1HPGDMGLLTHRA | |
| SCHEMBL14926460 | 0.80 | MGLL (0.67) | SMPD1ALDH1A1HPGDL3MBTL1MGLL | |
| SCHEMBL9307263 | 0.80 | SMPD1 (0.76) | SMPD1MGLLMAPTTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846366-B1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1846366-A1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006080477-A1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | SLC38A7, SLC7A1, SLC6A7 | SMPD1 3724/4885ALDH1A1 2442/4885HPGD 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.